Open AccessTissue plasminogen activator (tPA) treatment for COVID_19 associated acute respiratory distress syndrome (ARDS): A case report
Author(s) -
Muhammad Mazharul Hoque,
Motiul Islam,
Tarikul Hamid,
Rabiul Halim,
Rajib Hasan,
Kazi Nuruddin Ahmed
Publication year - 2021
Publication title -
bangladesh critical care journal
Language(s) - English
Resource type - Journals
eISSN - 2307-7654
pISSN - 2304-0009
DOI - 10.3329/bccj.v9i1.53059
Subject(s) - medicine , ards , diffuse alveolar damage , coagulopathy , respiratory failure , pneumonia , autopsy , etiology , covid-19 , tissue plasminogen activator , intensive care medicine , lung , respiratory system , respiratory distress , surgery , acute respiratory distress , disease , infectious disease (medical specialty)
Coagulopathy has proven to be a common complication of the novel coronavirus SARS-CoV-21. Some of the COVID-19 associated pneumonia patients exhibit relatively preserved lung compliance and high alveolar‐arterial oxygen gradient. Pathology reports consistently demonstrate diffuse pulmonary microthrombi on autopsy, consistent with a vascular occlusive etiology of respiratory failure rather than the more classic findings of ARDS2. Pulmonary microthrombi induced respiratory failure is very difficult to prove because the patients are so critically ill that transfer to CT suit to do CTPA often becomes unsafe for the patients. Moreover, performing V/Q scan is increasingly difficult in such settings. Here we report a case of severe COVID-19 associated respiratory failure who was treated with tissue plasminogen activator (tPA) on clinical ground.
Bangladesh Crit Care J March 2021; 9(1): 49-51